Bid Publish Date
25-Feb-2025, 11:20 pm
Bid End Date
13-Mar-2025, 2:00 pm
EMD
₹50,000
Location
Progress
Quantity
6600
Bid Type
Two Packet Bid
Public procurement opportunity for Directorate Of Medical And Rural Health Services Inj Bleomycin 15mg and 30mg, nj Gemcitabine 200 MG and 1g, Inj Vincristine 1MG and 2mg, Inj Carboplatin 50 150 450 and 600mg, Inj Cisplatin 50mg and 100mg, Inj Paclitaxel 150 mg and 300 mg, Inj Cyclophosphamide 500mg, Inj Bortezomib 2 and 2. 5 mg, Inj Albumin 20Percent Iv, Inj. Dexamethasone 4mg and 8mg, Inj Zoledronic acid 5mg, Bicalutamide tablets 50mg, Tab Lenalidomide 5 mg, Tab Valcivir 500 mg in BARAMULLA, JAMMU & KASHMIR. Quantity: 6600 issued by. Submission Deadline: 13-03-2025 14: 00: 00. View full details and respond.
Tender Category
Goods
Bid To RA
No
Bid To RA Enabled
No
Item Category
Inj Bleomycin 15mg and 30mg , nj Gemcitabine 200 MG and 1g , Inj Vincristine 1MG and 2mg , Inj Carboplatin 50 150 450 and 600mg , Inj Cisplatin 50mg and 100mg , Inj Paclitaxel 150 mg and 300 mg , Inj Cyclophosphamide 500mg , Inj Bortezomib 2 and 2.5 mg , Inj Albumin 20Percent Iv , Inj. Dexamethasone 4mg and 8mg , Inj Zoledronic acid 5mg , Bicalutamide tablets 50mg , Tab Lenalidomide 5 mg , Tab Valcivir 500 mg
End-to-end support — bid preparation, GeM registration, document filing & compliance by industry experts.
Free consultation · 24h response
Main Document
BOQ
BOQ
GEM_GENERAL_TERMS_AND_CONDITIONS
Inj Bleomycin 15mg and 30mg
Inj Bleomycin 15mg and 30mg
nj Gemcitabine 200 MG and 1g
nj Gemcitabine 200 MG and 1g
Inj Vincristine 1MG and 2mg
Inj Vincristine 1MG and 2mg
Inj Carboplatin 50 150 450 and 600mg
Inj Carboplatin 50 150 450 and 600mg
Inj Cisplatin 50mg and 100mg
Inj Cisplatin 50mg and 100mg
Inj Paclitaxel 150 mg and 300 mg
Inj Paclitaxel 150 mg and 300 mg
Inj Cyclophosphamide 500mg
Inj Cyclophosphamide 500mg
Inj Bortezomib 2 and 2.5 mg
Inj Bortezomib 2 and 2.5 mg
Inj Albumin 20Percent Iv
Inj Albumin 20Percent Iv
Inj. Dexamethasone 4mg and 8mg
Inj. Dexamethasone 4mg and 8mg
Inj Zoledronic acid 5mg
Inj Zoledronic acid 5mg
Bicalutamide tablets 50mg
Bicalutamide tablets 50mg
Tab Lenalidomide 5 mg
Tab Lenalidomide 5 mg
Tab Valcivir 500 mg
Tab Valcivir 500 mg
| Item # | Title | Description | Quantity | Unit | Consignee | Delivery (Days) | Price Trends |
|---|---|---|---|---|---|---|---|
| 1 | Inj Bleomycin 15mg and 30mg | Inj Bleomycin 15mg and 30mg | 50 | vials | msdhbpr01 | 10 | |
| 2 | nj Gemcitabine 200 MG and 1g | nj Gemcitabine 200 MG and 1g | 50 | vials | msdhbpr01 | 10 | |
| 3 | Inj Vincristine 1MG and 2mg | Inj Vincristine 1MG and 2mg | 50 | vials | msdhbpr01 | 10 | |
| 4 | Inj Carboplatin 50 150 450 and 600mg | Inj Carboplatin 50 150 450 and 600mg | 50 | vials | msdhbpr01 | 10 | |
| 5 | Inj Cisplatin 50mg and 100mg | Inj Cisplatin 50mg and 100mg | 50 | vials | msdhbpr01 | 10 | |
| 6 | Inj Paclitaxel 150 mg and 300 mg | Inj Paclitaxel 150 mg and 300 mg | 50 | vials | msdhbpr01 | 10 | |
| 7 | Inj Cyclophosphamide 500mg | Inj Cyclophosphamide 500mg | 50 | vials | msdhbpr01 | 10 | |
| 8 | Inj Bortezomib 2 and 2.5 mg | Inj Bortezomib 2 and 2.5 mg | 50 | vials | msdhbpr01 | 10 | |
| 9 | Inj Albumin 20Percent Iv | Inj Albumin 20Percent Iv | 50 | vials | msdhbpr01 | 10 | |
| 10 | Inj. Dexamethasone 4mg and 8mg | Inj. Dexamethasone 4mg and 8mg | 50 | vials | msdhbpr01 | 10 | |
| 11 | Inj Zoledronic acid 5mg | Inj Zoledronic acid 5mg | 50 | vials | msdhbpr01 | 10 | |
| 12 | Bicalutamide tablets 50mg | Bicalutamide tablets 50mg | 1,000 | stripes | msdhbpr01 | 10 | |
| 13 | Tab Lenalidomide 5 mg | Tab Lenalidomide 5 mg | 50 | vials | msdhbpr01 | 10 | |
| 14 | Tab Valcivir 500 mg | Tab Valcivir 500 mg | 5,000 | stripes | msdhbpr01 | 10 |
Experience Criteria
Past Performance
Bidder Turnover
Certificate (Requested in ATC)
OEM Authorization Certificate
OEM Annual Turnover
Compliance of BoQ specification and supporting document *In case any bidder is seeking exemption from Experience / Turnover Criteria
the supporting documents to prove his eligibility for exemption must be uploaded for evaluation by the buyer
| S.No | Seller | Item | Date | Status |
|---|---|---|---|---|
| 1 | M/S SAHARA MEDICAL STORE Under PMA | - | 13-03-2025 13:52:39 | |
| 2 | SUNIL PHARMACY Under PMA | - | 13-03-2025 13:45:13 |
Key insights about JAMMU AND KASHMIR tender market
The eligibility requirements for participating in tenders issued by the Health and Family Welfare Department Jammu and Kashmir include being a registered business entity with a valid GST registration. Additionally, entities must hold relevant licenses to supply pharmaceuticals. Demonstrating experience in previous pharmaceutical supplies is also crucial for qualification. Businesses must provide evidence of their operational capabilities and financial stability to manage contract obligations.
Bidders must submit various certificates with their tender proposals, including Certificates of Analysis (CoA) for each pharmaceutical product offered. Compliance with Good Manufacturing Practices (GMP) and relevant quality assurance certifications is essential. Additionally, pharmaceutical registration certificates and tax compliance documents should be included to validate the bidder's credentials and adherence to regulatory standards.
To register for submitting a tender, interested bidders must create an account on the official procurement portal designated by the Health and Family Welfare Department. This registration typically requires providing business and contact information, tax registrations, and relevant certifications. After successful account activation, bidders will have access to participate in upcoming tenders and necessary documentation for their submissions.
For submissions related to the tender, it is recommended that bidders use commonly accepted document formats such as PDF or Word files. Clear guidelines will be available in the tender documentation on how to format and submit. Avoid using unusual or unsupported formats to ensure that the submitted documents are easily accessible and reviewable by the evaluation team.
Key considerations for price evaluation include the total cost proposed by bidders in comparison to the budget laid out by the Health and Family Welfare Department. This includes analyzing pricing structures, terms of payment, and any additional costs associated with compliance. The evaluation will also focus on the quality assurances provided alongside the cost to ensure that the best overall value is achieved for the healthcare sector.
Sign up now to access all documents
Main Document
BOQ
BOQ
GEM_GENERAL_TERMS_AND_CONDITIONS